| Literature DB >> 20569505 |
Rossella De Cegli1, Antonio Romito, Simona Iacobacci, Lei Mao, Mario Lauria, Anthony O Fedele, Joachim Klose, Christelle Borel, Patrick Descombes, Stylianos E Antonarakis, Diego di Bernardo, Sandro Banfi, Andrea Ballabio, Gilda Cobellis.
Abstract
BACKGROUND: Dosage imbalance is responsible for several genetic diseases, among which Down syndrome is caused by the trisomy of human chromosome 21.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20569505 PMCID: PMC2911112 DOI: 10.1186/gb-2010-11-6-r64
Source DB: PubMed Journal: Genome Biol ISSN: 1474-7596 Impact factor: 13.583
Figure 1Schematic representation of the experimental strategy used. A set of 32 genes, 29 murine orthologs of HSA21 genes and 3 human coding sequences, were cloned into the pPthC vector [19] and nucleofected along with a pCAGGS-Cre recombinase vector [41] into EBRTcH3 (EB3) cells. Puromycin-resistant clones were isolated and grown in medium deprived of tetracycline for varying periods of time to perform a time course of induction. The inducibility of selected clones was evaluated by q-PCR. Global transcriptome and proteome analysis was performed by hybridization onto an Affymetrix gene chip and by large-gel two-dimensional gel electrophoresis (2DGE), respectively, to delineate the consequences of gene dosage imbalance on a single gene basis. WB, western blot.
Figure 2Average induction of the 32 inducible clones by q-PCR. Baseline expression (0 hours of induction - white bars), following induction of transgene (after 24 to 48 hours of growth in medium deprived of Tc - gray bars), and relative expression in the parental cell line (EB3 - black bars). (a) The 13 transcription factors and the single transcriptional activator (Dscr1-Rcan1); (b) the 6 kinases; (c) the other 12 genes with diverse molecular functions. Asterisks indicate statistically significant expression changes (t-test with false discovery rate <0.05). The errors bars are calculated on the biological triplicates.
Gene Ontology enrichment analysis for six out of seven effective genes whose overexpression perturbed the mES transcriptome in a statistically significant manner
| Gene | Gene Ontology term | FDR | Fold enrichment | Reference |
|---|---|---|---|---|
| Negative regulation of progression through cell cycle | 2.8 | 1.5 | [ | |
| Positive regulation of cell proliferation | 0.5 | 1.5 | [ | |
| Vasculature development | 0.1 | 1.5 | [ | |
| Blood vessel development | 0.2 | 1.5 | [ | |
| Blood vessel morphogenesis | 0.1 | 1.6 | [ | |
| Angiogenesis | 0.1 | 1.6 | [ | |
| Regulation of myeloid cell differentiation | 0.8 | 2.1 | [ | |
| Skeletal development | 0.2 | 1.5 | [ | |
| Skeletal morphogenesis | 1.7 | 2.5 | [ | |
| Regulation of cell differentiation | 0.0 | 1.7 | [ | |
| Anatomical structure formation | 0.2 | 1.5 | [ | |
| Angiogenesis | 0.0 | 1.6 | [ | |
| Regulation of cell differentiation | 0.8 | 1.5 | [ | |
| Cell growth | 2.3 | 1.5 | [ | |
| Regulation of cell migration | 1.3 | 1.8 | [ | |
| Negative regulation of transcription, DNA-dependent | 0.5 | 1.5 | [ | |
| Muscle cell differentiation | 2.0 | 4.3 | [ | |
| Nervous system development | 0,1 | 2.0 | [ | |
| Negative regulation of transcription, DNA-dependent | 3.6 | 2.6 | [ | |
| Organ morphogenesis | 0.5 | 1.6 | [ | |
| Placenta development | 1.3 | 4.3 | [ | |
| Negative regulation of progression through cell cycle | 3.6 | 2.1 | [ | |
| Cellular macromolecule catabolic process | 2.0 | 2.7 | [ | |
| Cellular carbohydrate metabolic process | 0.0 | 4.1 | [ | |
| Amino acid biosynthetic process | 0.6 | 7.3 | [ | |
| Cell morphogenesis | 0.0 | 1.6 | [ | |
| Regulation of progression through cell cycle | 0.0 | 1.7 | [ | |
| Regulation of cell differentiation | 0.4 | 1.9 | [ | |
| Cell migration | 4.0 | 1.5 | [ |
Perturbation of the mES transcriptome was as assessed by microarray analysis. GO analysis was performed on the list of differentially expressed genes using the DAVID tool, restricting the output to biological process terms of levels 4 and 5, with a significance threshold FDR < 5% and fold enrichment ≥ 1.5%. Supporting references confirming GO analysis are reported in the 'References' column.
Figure 3The basal expression level and dosage sensitivity of HSA21 genes in mES cells. The effective genes are highlighted in blue, and the silent genes in red. (a) Selected HSA21 genes sorted according to their average expression level in mES cells, from the most (gene rank = 1) to the least expressed. (b) Selected HSA21 genes sorted according to the total length of the 'disordered' region of the encoded protein (measured with the GlobPlot tool).
Figure 4Comparison of differentially expressed genes following single gene over-expression in our cell bank mouse ES cell lines versus transchromosomic Tc1 mouse ES cell lines. The colors indicate the overexpression experiment in which the expression value was found to be significant; for genes whose expression was significant in more than one overexpression experiment, only the one with the largest absolute value was considered. A total of 168 points are in the graph, of which 125 fall in same-sign quadrants. The regression line was forced to pass through the origin in order to highlight the general trend with respect to zero.
Correlation between differential protein expression by 2DGE (protein ratio) and differential gene expression by microarray (mRNA ratio)
| Spot ID* | Gene | Protein name | Protein ratio 48 h/0 h* | mRNA ratio 24 h/0 h |
|---|---|---|---|---|
| 3214 | Ubiquitin carboxy-terminal hydrolase L1 | 0.58 | 0.63 | |
| 662 | Developmental pluripotency associated 4 isoform 1 | 0.65 | 0.75 | |
| 3549 | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF-II mRNA-binding protein 2) (IMP-2) | 0.65 | 1.39 | |
| 2836 | Signal-induced proliferation-associated 1-like protein 1 | 0.74 | 1.54 | |
| 425 | Cytosol aminopeptidase (Leucine aminopeptidase) (LAP) (Leucyl aminopeptidase) (Leucine aminopeptidase 3) (Proline aminopeptidase)(Prolyl aminopeptidase) | 0.76 | 0.72 | |
| 2512 | 60 kDa heat shock protein, mitochondrial precursor (Hsp60) (60 kDa chaperonin) (CPN60) (Heat shock protein 60) (HSP-60) (Mitochondrial matrix protein P1) (HSP-65) | 0.78 | 0.75 | |
| 3410 | Eukaryotic translation initiation factor 1A, Y-linked | 0.8 | 0.76 | |
| 403 | Pyruvate kinase isozyme M2 | 1.26 | 3.05 | |
| 935 | D-beta-hydroxybutyrate dehydrogenase, mitochondrial precursor | 1.31 | 1.53 | |
| 645 | Serine (or cysteine) proteinase inhibitor, clade H, member 1 | 1.44 | 1.36 | |
| 2920 | Lactate dehydrogenase 2, B chain | 1.46 | 0.64 | |
| 3562 | Coactosin-like 1 | 1.62 | 1.39 | |
| 3653 | S100 calcium binding protein A11 (calizzarin) | 1.89 | 1.18 | |
| 3144 | Septin 1 | 2.28 | 0.71 | |
| 1134 | Glutathione S-transferase omega 1 | 2.77 | 3.73 | |
| 3588 | Fatty acid binding protein 3, muscle and heart | 3.05 | 2.2 | |
| 3078 | Apolipoprotein E | 3.28 | 0.8 |
Only two gene/protein pairs, apoE and Sept1, showed bifurcated regulation in protein and microarray assays.